Cerene provides an FDA‑cleared, office‑based cryotherapy system that ablates the endometrial lining to treat heavy menstrual bleeding without general anesthesia. Using a single‑use probe, the procedure delivers controlled freezing in under 10 minutes, allowing gynecologists to perform the treatment in a standard exam room with minimal downtime and pain.
Funding
$5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Heavy menstrual bleeding (menorrhagia) affects roughly 20% of premenopausal women, causing excessive blood loss, severe cramping, and disruption of daily activities, work, and social life. Existing surgical options often require general anesthesia, operating‑room resources, and extended recovery periods, limiting accessibility for many patients.
Solution
Cerene offers an office‑based cryotherapy system that ablates the endometrial lining to treat heavy menstrual bleeding without the need for general anesthesia. The procedure uses a single‑use cryoprobe to deliver controlled freezing, achieving tissue ablation in a matter of minutes while the patient remains seated in the physician’s office. Clinical data show that most patients experience normal, light, or absent periods and a marked reduction in cramping after treatment. The device is designed for use by trained physicians and includes built‑in safety features to minimize intra‑procedural discomfort, with 92% of patients reporting pain at or below the median acceptable level. By eliminating the need for an operating room, Cerene reduces procedural costs and recovery time, enabling quicker return to normal activities.
Target Audience
The primary customers are gynecologists and OB‑GYN practices seeking an in‑office solution for premenopausal women with heavy menstrual bleeding who have completed childbearing. The device also serves patients looking for a minimally invasive alternative to hysterectomy or operative hysteroscopic ablation.
Features
- Single‑use cryotherapy probe that delivers precise, controlled freezing to the endometrial tissue for consistent ablation
- Office‑based workflow: procedure performed in a standard exam room without general anesthesia or surgical facilities
- Rapid treatment cycle (typically under 10 minutes) with minimal post‑procedure downtime
- Integrated patient‑monitoring sensors that track uterine temperature and ensure safety thresholds are maintained
- FDA‑cleared device with documented efficacy: >90% of patients report normal or light periods and reduced cramping
- Low‑pain protocol: real‑time feedback and adjustable freeze parameters keep patient discomfort within acceptable limits
- Compatibility with standard gynecologic equipment and electronic health record documentation via secure data export
- Comprehensive training program for physicians to ensure proper device handling and patient selection